Medical - Devices
Compare Stocks
5 / 10Stock Comparison
VMD vs EHAB vs ADUS vs OPCH vs HCSG
Revenue, margins, valuation, and 5-year total return — side by side.
Medical - Care Facilities
Medical - Care Facilities
Medical - Care Facilities
Medical - Care Facilities
VMD vs EHAB vs ADUS vs OPCH vs HCSG — Key Financials
Market cap, revenue, margins, and valuation side-by-side.
| Company Snapshot | |||||
|---|---|---|---|---|---|
| Industry | Medical - Devices | Medical - Care Facilities | Medical - Care Facilities | Medical - Care Facilities | Medical - Care Facilities |
| Market Cap | $343M | $706M | $1.86B | $3.21B | $1.65B |
| Revenue (TTM) | $287M | $1.06B | $1.45B | $5.67B | $1.84B |
| Net Income (TTM) | $15M | $-3M | $100M | $206M | $59M |
| Gross Margin | 57.5% | 36.1% | 32.5% | 18.0% | 13.3% |
| Operating Margin | 8.2% | 7.2% | 9.8% | 5.9% | 3.0% |
| Forward P/E | 18.6x | 22.9x | 14.3x | 11.2x | 21.3x |
| Total Debt | $16M | $500M | $209M | $0.00 | $25M |
| Cash & Equiv. | $14M | $44M | $82M | $233M | $161M |
VMD vs EHAB vs ADUS vs OPCH vs HCSG — Long-Term Stock Performance
Price return indexed to 100 at period start. Dividends excluded.
| Stock | Jun 22 | May 26 | Return |
|---|---|---|---|
| Viemed Healthcare, … (VMD) | 100 | 166.2 | +66.2% |
| Enhabit, Inc. (EHAB) | 100 | 60.0 | -40.0% |
| Addus HomeCare Corp… (ADUS) | 100 | 119.6 | +19.6% |
| Option Care Health,… (OPCH) | 100 | 73.8 | -26.2% |
| Healthcare Services… (HCSG) | 100 | 132.5 | +32.5% |
Price return only. Dividends and distributions are not included.
Quick Verdict: VMD vs EHAB vs ADUS vs OPCH vs HCSG
Each card shows where this stock fits in a portfolio — not just who wins on paper.
VMD is the #2 pick in this set and the best alternative if income & stability and growth exposure is your priority.
- Dividend streak 2 yrs, beta 0.85
- Rev growth 20.5%, EPS growth 32.1%, 3Y rev CAGR 24.9%
- 7.5% ROA vs EHAB's -0.3%, ROIC 11.6% vs 4.5%
EHAB ranks third and is worth considering specifically for sleep-well-at-night and defensive.
- Lower volatility, beta 0.35, Low D/E 88.6%, current ratio 1.63x
- Beta 0.35, current ratio 1.63x
- Beta 0.35 vs HCSG's 1.14
ADUS has the current edge in this matchup, primarily because of its strength in long-term compounding.
- 411.7% 10Y total return vs OPCH's 95.0%
- 23.2% revenue growth vs EHAB's 2.4%
- 6.9% margin vs EHAB's -0.3%
OPCH is the clearest fit if your priority is value.
- Lower P/E (11.2x vs 21.3x)
HCSG is the clearest fit if your priority is momentum.
- +60.7% vs OPCH's -35.3%
See the full category breakdown
| Category | Winner | Why |
|---|---|---|
| Growth | 23.2% revenue growth vs EHAB's 2.4% | |
| Value | Lower P/E (11.2x vs 21.3x) | |
| Quality / Margins | 6.9% margin vs EHAB's -0.3% | |
| Stability / Safety | Beta 0.35 vs HCSG's 1.14 | |
| Dividends | Tie | None of these 5 stocks pay a meaningful dividend |
| Momentum (1Y) | +60.7% vs OPCH's -35.3% | |
| Efficiency (ROA) | 7.5% ROA vs EHAB's -0.3%, ROIC 11.6% vs 4.5% |
VMD vs EHAB vs ADUS vs OPCH vs HCSG — Revenue Breakdown by Segment
How each company's revenue is distributed across its business units
VMD vs EHAB vs ADUS vs OPCH vs HCSG — Financial Metrics
Side-by-side numbers across 5 stocks — who leads on profitability, valuation, growth, and risk.
Who Leads Where
EHAB leads in 2 of 6 categories
HCSG leads 2 • ADUS leads 1 • OPCH leads 1 • VMD leads 0
Explore the data ↓Income & Cash Flow (Last 12 Months)
ADUS leads this category, winning 3 of 6 comparable metrics.
Income & Cash Flow (Last 12 Months)
OPCH is the larger business by revenue, generating $5.7B annually — 19.8x VMD's $287M. ADUS is the more profitable business, keeping 6.9% of every revenue dollar as net income compared to EHAB's -0.3%. On growth, VMD holds the edge at +27.5% YoY revenue growth, suggesting stronger near-term business momentum.
| Metric | |||||
|---|---|---|---|---|---|
| RevenueTrailing 12 months | $287M | $1.1B | $1.4B | $5.7B | $1.8B |
| EBITDAEarnings before interest/tax | $46M | $98M | $159M | $406M | $72M |
| Net IncomeAfter-tax profit | $15M | -$3M | $100M | $206M | $59M |
| Free Cash FlowCash after capex | $26M | $81M | $137M | $244M | $139M |
| Gross MarginGross profit ÷ Revenue | +57.5% | +36.1% | +32.5% | +18.0% | +13.3% |
| Operating MarginEBIT ÷ Revenue | +8.2% | +7.2% | +9.8% | +5.9% | +3.0% |
| Net MarginNet income ÷ Revenue | +5.2% | -0.3% | +6.9% | +3.6% | +3.2% |
| FCF MarginFCF ÷ Revenue | +9.0% | +7.6% | +9.5% | +4.3% | +7.6% |
| Rev. Growth (YoY)Latest quarter vs prior year | +27.5% | +1.9% | +7.7% | +1.3% | +6.6% |
| EPS Growth (YoY)Latest quarter vs prior year | 0.0% | +2.9% | +17.2% | +3.6% | +175.0% |
Valuation Metrics
EHAB leads this category, winning 3 of 6 comparable metrics.
Valuation Metrics
At 16.1x trailing earnings, OPCH trades at a 43% valuation discount to HCSG's 28.5x P/E. On an enterprise value basis, VMD's 7.0x EV/EBITDA is more attractive than HCSG's 23.2x.
| Metric | |||||
|---|---|---|---|---|---|
| Market CapShares × price | $343M | $706M | $1.9B | $3.2B | $1.7B |
| Enterprise ValueMkt cap + debt − cash | $345M | $1.2B | $2.0B | $3.0B | $1.5B |
| Trailing P/EPrice ÷ TTM EPS | 24.16x | -152.21x | 19.11x | 16.15x | 28.47x |
| Forward P/EPrice ÷ next-FY EPS est. | 18.63x | 22.86x | 14.28x | 11.18x | 21.30x |
| PEG RatioP/E ÷ EPS growth rate | — | — | 0.95x | — | — |
| EV / EBITDAEnterprise value multiple | 7.00x | 13.47x | 12.79x | 7.28x | 23.20x |
| Price / SalesMarket cap ÷ Revenue | 1.27x | 0.67x | 1.30x | 0.57x | 0.90x |
| Price / BookPrice ÷ Book value/share | 2.54x | 1.24x | 1.69x | 2.53x | 3.30x |
| Price / FCFMarket cap ÷ FCF | 28.73x | 10.74x | 17.89x | 12.42x | 11.87x |
Profitability & Efficiency
OPCH leads this category, winning 4 of 9 comparable metrics.
Profitability & Efficiency
OPCH delivers a 15.3% return on equity — every $100 of shareholder capital generates $15 in annual profit, vs $-1 for EHAB. HCSG carries lower financial leverage with a 0.05x debt-to-equity ratio, signaling a more conservative balance sheet compared to EHAB's 0.89x. On the Piotroski fundamental quality scale (0–9), ADUS scores 7/9 vs VMD's 4/9, reflecting strong financial health.
| Metric | |||||
|---|---|---|---|---|---|
| ROE (TTM)Return on equity | +10.5% | -0.6% | +9.3% | +15.3% | +11.8% |
| ROA (TTM)Return on assets | +7.5% | -0.3% | +7.0% | +6.0% | +7.3% |
| ROICReturn on invested capital | +11.6% | +4.5% | +8.8% | +15.3% | +9.0% |
| ROCEReturn on capital employed | +13.2% | +6.0% | +10.9% | +12.8% | +7.7% |
| Piotroski ScoreFundamental quality 0–9 | 4 | 6 | 7 | 5 | 7 |
| Debt / EquityFinancial leverage | 0.11x | 0.89x | 0.19x | — | 0.05x |
| Net DebtTotal debt minus cash | $2M | $456M | $127M | -$233M | -$136M |
| Cash & Equiv.Liquid assets | $14M | $44M | $82M | $233M | $161M |
| Total DebtShort + long-term debt | $16M | $500M | $209M | $0 | $25M |
| Interest CoverageEBIT ÷ Interest expense | 14.61x | 0.19x | 14.45x | 5.50x | 33.02x |
Total Returns (Dividends Reinvested)
HCSG leads this category, winning 3 of 6 comparable metrics.
Total Returns (Dividends Reinvested)
A $10,000 investment in OPCH five years ago would be worth $12,311 today (with dividends reinvested), compared to $5,516 for EHAB. Over the past 12 months, HCSG leads with a +60.7% total return vs OPCH's -35.3%. The 3-year compound annual growth rate (CAGR) favors HCSG at 15.4% vs OPCH's -10.0% — a key indicator of consistent wealth creation.
| Metric | |||||
|---|---|---|---|---|---|
| YTD ReturnYear-to-date | +23.8% | +51.7% | -6.6% | -36.4% | +32.9% |
| 1-Year ReturnPast 12 months | +39.3% | +42.3% | -10.1% | -35.3% | +60.7% |
| 3-Year ReturnCumulative with dividends | -17.1% | +2.2% | +19.0% | -27.2% | +53.6% |
| 5-Year ReturnCumulative with dividends | -3.8% | -44.8% | +3.4% | +23.1% | -17.7% |
| 10-Year ReturnCumulative with dividends | +398.4% | -44.8% | +411.7% | +95.0% | -24.9% |
| CAGR (3Y)Annualised 3-year return | -6.1% | +0.7% | +6.0% | -10.0% | +15.4% |
Risk & Volatility
EHAB leads this category, winning 2 of 2 comparable metrics.
Risk & Volatility
EHAB is the less volatile stock with a 0.35 beta — it tends to amplify market swings less than HCSG's 1.14 beta. A beta below 1.0 means the stock typically moves less than the S&P 500. EHAB currently trades 97.0% from its 52-week high vs OPCH's 55.7% drawdown — a narrower gap to the peak suggests stronger recent price momentum.
| Metric | |||||
|---|---|---|---|---|---|
| Beta (5Y)Sensitivity to S&P 500 | 0.85x | 0.35x | 0.57x | 0.41x | 1.14x |
| 52-Week HighHighest price in past year | $10.18 | $14.22 | $124.44 | $36.80 | $24.39 |
| 52-Week LowLowest price in past year | $5.93 | $6.47 | $90.89 | $18.01 | $12.66 |
| % of 52W HighCurrent price vs 52-week peak | +87.8% | +97.0% | +80.0% | +55.7% | +94.5% |
| RSI (14)Momentum oscillator 0–100 | 46.2 | 59.7 | 51.2 | 24.7 | 63.2 |
| Avg Volume (50D)Average daily shares traded | 314K | 1.1M | 236K | 2.4M | 672K |
Analyst Outlook
HCSG leads this category, winning 1 of 1 comparable metric.
Analyst Outlook
Analyst consensus: VMD as "Buy", EHAB as "Hold", ADUS as "Buy", OPCH as "Buy", HCSG as "Hold". Consensus price targets imply 57.9% upside for OPCH (target: $32) vs -1.9% for EHAB (target: $14).
| Metric | |||||
|---|---|---|---|---|---|
| Analyst RatingConsensus buy/hold/sell | Buy | Hold | Buy | Buy | Hold |
| Price TargetConsensus 12-month target | — | $13.53 | $128.67 | $32.38 | $24.50 |
| # AnalystsCovering analysts | 1 | 11 | 16 | 14 | 15 |
| Dividend YieldAnnual dividend ÷ price | — | — | — | — | — |
| Dividend StreakConsecutive years of raises | 2 | 0 | 2 | 1 | 20 |
| Dividend / ShareAnnual DPS | — | — | — | — | — |
| Buyback YieldShare repurchases ÷ mkt cap | +3.9% | 0.0% | 0.0% | +9.7% | +3.7% |
EHAB leads in 2 of 6 categories (Valuation Metrics, Risk & Volatility). HCSG leads in 2 (Total Returns, Analyst Outlook).
VMD vs EHAB vs ADUS vs OPCH vs HCSG: Key Questions Answered
10 questions · data-driven answers · updated daily
01Is VMD or EHAB or ADUS or OPCH or HCSG a better buy right now?
For growth investors, Addus HomeCare Corporation (ADUS) is the stronger pick with 23.
2% revenue growth year-over-year, versus 2. 4% for Enhabit, Inc. (EHAB). Option Care Health, Inc. (OPCH) offers the better valuation at 16. 1x trailing P/E (11. 2x forward), making it the more compelling value choice. Analysts rate Viemed Healthcare, Inc. (VMD) a "Buy" — based on 1 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.
02Which has the better valuation — VMD or EHAB or ADUS or OPCH or HCSG?
On trailing P/E, Option Care Health, Inc.
(OPCH) is the cheapest at 16. 1x versus Healthcare Services Group, Inc. at 28. 5x. On forward P/E, Option Care Health, Inc. is actually cheaper at 11. 2x.
03Which is the better long-term investment — VMD or EHAB or ADUS or OPCH or HCSG?
Over the past 5 years, Option Care Health, Inc.
(OPCH) delivered a total return of +23. 1%, compared to -44. 8% for Enhabit, Inc. (EHAB). Over 10 years, the gap is even starker: ADUS returned +411. 7% versus EHAB's -44. 8%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.
04Which is safer — VMD or EHAB or ADUS or OPCH or HCSG?
By beta (market sensitivity over 5 years), Enhabit, Inc.
(EHAB) is the lower-risk stock at 0. 35β versus Healthcare Services Group, Inc. 's 1. 14β — meaning HCSG is approximately 224% more volatile than EHAB relative to the S&P 500. On balance sheet safety, Healthcare Services Group, Inc. (HCSG) carries a lower debt/equity ratio of 5% versus 89% for Enhabit, Inc. — giving it more financial flexibility in a downturn.
05Which is growing faster — VMD or EHAB or ADUS or OPCH or HCSG?
By revenue growth (latest reported year), Addus HomeCare Corporation (ADUS) is pulling ahead at 23.
2% versus 2. 4% for Enhabit, Inc. (EHAB). On earnings-per-share growth, the picture is similar: Enhabit, Inc. grew EPS 97. 1% year-over-year, compared to 3. 3% for Option Care Health, Inc.. Over a 3-year CAGR, VMD leads at 24. 9% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.
06Which has better profit margins — VMD or EHAB or ADUS or OPCH or HCSG?
Addus HomeCare Corporation (ADUS) is the more profitable company, earning 6.
7% net margin versus -0. 4% for Enhabit, Inc. — meaning it keeps 6. 7% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: ADUS leads at 9. 7% versus 2. 6% for HCSG. At the gross margin level — before operating expenses — VMD leads at 57. 5%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.
07Is VMD or EHAB or ADUS or OPCH or HCSG more undervalued right now?
On forward earnings alone, Option Care Health, Inc.
(OPCH) trades at 11. 2x forward P/E versus 22. 9x for Enhabit, Inc. — 11. 7x cheaper on a one-year earnings basis. Analyst consensus price targets imply the most upside for OPCH: 57. 9% to $32. 38.
08Which pays a better dividend — VMD or EHAB or ADUS or OPCH or HCSG?
None of the stocks in this comparison currently pay a material dividend.
All are effectively zero-yield and should be held for capital appreciation rather than income.
09Is VMD or EHAB or ADUS or OPCH or HCSG better for a retirement portfolio?
For long-horizon retirement investors, Addus HomeCare Corporation (ADUS) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0.
57), +411. 7% 10Y return). Both have compounded well over 10 years (ADUS: +411. 7%, HCSG: -24. 9%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.
10What are the main differences between VMD and EHAB and ADUS and OPCH and HCSG?
Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.
In terms of investment character: VMD is a small-cap high-growth stock; EHAB is a small-cap quality compounder stock; ADUS is a small-cap high-growth stock; OPCH is a small-cap deep-value stock; HCSG is a small-cap quality compounder stock. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.
Find Stocks Like These
Explore pre-built screens for each stock's profile, or build a custom screen to find stocks that outperform all of them.
You Might Also Compare
Based on how these companies actually compete and overlap — not just which sector they're filed under.